These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11604550)

  • 1. Capecitabine: a novel agent for the treatment of solid tumors.
    Johnston PG; Kaye S
    Anticancer Drugs; 2001 Sep; 12(8):639-46. PubMed ID: 11604550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine: effective oral fluoropyrimidine chemotherapy.
    McKendrick J; Coutsouvelis J
    Expert Opin Pharmacother; 2005 Jun; 6(7):1231-9. PubMed ID: 15957975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
    Folprecht G; Köhne CH
    Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical considerations in the use of oral fluoropyrimidines.
    Hoff PM
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
    Malet-Martino M; Martino R
    Oncologist; 2002; 7(4):288-323. PubMed ID: 12185293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
    Seidman AD; O'Shaughnessy J; Misset JL
    Oncologist; 2002; 7 Suppl 6():20-8. PubMed ID: 12454316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
    Wagstaff AJ; Ibbotson T; Goa KL
    Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
    Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
    Van Cutsem E; Verslype C; Tejpar S
    Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational development of capecitabine.
    Venturini M
    Eur J Cancer; 2002 Feb; 38 Suppl 2():3-9. PubMed ID: 11841929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
    Aprile G; Mazzer M; Moroso S; Puglisi F
    Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer.
    Cassata A; Procoplo G; Alù M; Ferrari L; Ferrario E; Beretta E; Longarini R; Busto G; De Candis D; Bajetta E
    Tumori; 2001; 87(6):364-71. PubMed ID: 11989587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of fluoropyrimidine therapy: from intravenous to oral.
    Hoff PM; Cassidy J; Schmoll HJ
    Oncologist; 2001; 6 Suppl 4():3-11. PubMed ID: 11585968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluation of capecitabine in breast cancer.
    Daniele G; Gallo M; Piccirillo MC; Giordano P; D'Alessio A; Del Giudice A; La Porta ML; Perrone F; Normanno N; De Luca A
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):225-35. PubMed ID: 23301520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rational development of capecitabine from the laboratory to the clinic.
    Pentheroudakis G; Twelves C
    Anticancer Res; 2002; 22(6B):3589-96. PubMed ID: 12552961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of Xeloda in colorectal cancer and other solid tumors.
    Cassidy J
    Oncology; 1999 Jul; 57 Suppl 1():27-32. PubMed ID: 10436414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating oxaliplatin into the management of colorectal cancer.
    Schmoll HJ; Cassidy J
    Oncologist; 2001; 6 Suppl 4():24-8. PubMed ID: 11585971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.